节点文献

参苓白术散加减联合阿帕替尼治疗晚期胃癌的临床效果

Clinical effect of modified Shenling Baizhu Powder combined with apatinib in treating advanced gastric cancer

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 李豫; 凌博凡; 薛维伟; 戴虹;

【Author】 LI Yu;LING Bofan;XUE Weiwei;DAI Hong;Department of Oncology,Jiangsu Provincial Hospital of Traditional Chinese Medicine;

【通讯作者】 戴虹;

【机构】 江苏省中医院肿瘤内科;

【摘要】 目的观察参苓白术散加减联合阿帕替尼治疗晚期胃癌的临床效果。方法将60例患者随机分为2组,每组30例。治疗组采用参苓白术散加减联合阿帕替尼方案治疗,对照组采用阿帕替尼单药靶向治疗。比较2组治疗效果及不良反应发生率。结果治疗组疾病控制率和中医证候总有效率高于对照组,1级以上不良反应发生率低于对照组,差异有统计学意义(P <0.05)。结论参苓白术散加减联合阿帕替尼治疗晚期胃癌的临床疗效优于阿帕替尼单药,能够减轻阿帕替尼的毒副反应,改善生活质量。

【Abstract】 Objective To observe the clinical efficacy of modified Shenling Baizhu Powder combined with apatinib in the treatment of advanced gastric cancer. Methods A total of 60 patients were randomly divided into two groups,with 30 cases in each group. The treatment group was treated with modified Shenling Baizhu Powder combined with apatinib,while the control group was only treated with apatinib. The treatment effect and the incidence of adverse reactions were compared between the two groups. Results The disease control rate and effective rate of traditional Chinese medicine syndrome of the treatment group were significantly higher,the incidence of adverse reaction above grading one was significantly lower than that of the control group( P < 0. 05). Conclusion The clinical effect of modified Shenling Baizhu Powder combined with apatinib in the treatment of advanced gastric cancer is better than that of apatinib alone,and combined treatment can reduce the adverse reactions of apatinib as well as improve the quality of life.

【基金】 江苏省自然科学基金项目(BK20181097);江苏省中医药科技发展计划人才项目(RC201904);江苏省中医院院级课题项目(Y2019CX03)
  • 【文献出处】 实用临床医药杂志 ,Journal of Clinical Medicine in Practice , 编辑部邮箱 ,2020年24期
  • 【分类号】R735.2
  • 【被引频次】8
  • 【下载频次】196
节点文献中: 

本文链接的文献网络图示:

本文的引文网络